Natrol Q2 earnings
This article was originally published in The Tan Sheet
Natrol reported net income of $100,000 on net sales of $16.6 mil. during the second-quarter (ended June 30) marking the company's "second consecutive quarter of profitability," Natrol President and CEO Wayne Bos said Aug. 14. The gains represented a turnaround from the first two quarters of 2005 when Natrol reported a net loss of $300,000 on net sales of $37.3 mil. "We have achieved profitability by being sharply-focused on the core business," Bos said...
You may also be interested in...
An exclusive manufacturing and distribution deal with H57 Nutrition for Original South African H57 Hoodia is a feather in Natrol's cap following several acquisitions and licensing deals in the past three weeks
Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.
To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.